How much is the approximate market price of a box of trametinib targeted drug?

Trametinib is a MEK inhibitor targeted drug developed by Novartis. It is mainly used to inhibit the activation of MEK1 and MEK2 in the MAPK signaling pathway and block the division and growth of tumor cells. Its core indication is the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations, usually in combination with the BRAF inhibitor dabrafenib. In addition, trametinib has also been included in the treatment plan for BRAF mutation-positive non-small cell lung cancer and certain rare tumors such as thyroid cancer and brain glioma, and has application prospects in both children and adult patients.

In recent years, the drug has been approved for use in the above-mentioned indications in China and included in the national medical insurance catalog, which has greatly reduced the financial burden on patients. In terms of price, the domestic market currently mainly circulates two packaging specifications: 2mg×30 tablets and 0.5mg×30 tablets. The price of original research drugs is relatively high, usually about 10,000 yuan per box for 2 mg. When they are not included in medical insurance, they put great financial pressure on most patients. However, the medical insurance policy has made it clear that patients diagnosed as BRAF mutation-positive and meeting treatment standards can enjoy a certain proportion of medical insurance reimbursement, which greatly improves accessibility.

At the same time, there are multiple versions of trametinib available in overseas markets. For example, the price of the original drug in Turkey is relatively low, with a box of2mg priced at about 7,000 yuan. Countries such as Laos and Bangladesh also produce generic drugs. Their ingredients are basically the same as the original drugs, but the price is only about 1,000 to 1,500 yuan, making them the choice of many patients to obtain them through international drug purchasing channels. However, it is worth special reminder that the overseas version of drug purchase has problems such as exchange rate fluctuations. Patients purchase drugs under the guidance of doctors and through formal channels to ensure the continuity and safety of treatment.

Reference materials:https://go.drugbank.com/drugs/DB08911